BCTX Key Statistics, Chart & Performance
The current stock price of BCTX is 8.5 USD. In the past month the price decreased by -36.66%. In the past year, price decreased by -99.42%.
BCTX Latest News, Press Relases and Analysis
BCTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.29 | 405.44B | ||
| AMGN | AMGEN INC | 15.29 | 179.97B | ||
| GILD | GILEAD SCIENCES INC | 15.3 | 155.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.42 | 108.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.92 | 80.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 851.43 | 56.92B | ||
| INSM | INSMED INC | N/A | 43.74B | ||
| NTRA | NATERA INC | N/A | 32.75B | ||
| BIIB | BIOGEN INC | 10.56 | 25.92B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.08 | 21.58B | ||
| INCY | INCYTE CORP | 16.55 | 20.75B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.12B |
Related stock screener links
About BCTX
Company Profile
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. The company is headquartered in West Vancouver, British Columbia and currently employs 20 full-time employees. The company went IPO on 2006-10-12. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The firm is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. The company is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Company Info
BRIACELL THERAPEUTICS CORP
Suite 300 - Bellevue Centre, 235 -15th Street
West Vancouver BRITISH COLUMBIA V7T 2X1 CA
CEO: William V. Williams
Employees: 20
Phone: 16049211810
BRIACELL THERAPEUTICS CORP / BCTX FAQ
What does BRIACELL THERAPEUTICS CORP do?
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. The company is headquartered in West Vancouver, British Columbia and currently employs 20 full-time employees. The company went IPO on 2006-10-12. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The firm is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. The company is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
What is the current price of BCTX stock?
The current stock price of BCTX is 8.5 USD. The price increased by 6.25% in the last trading session.
Does BCTX stock pay dividends?
BCTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of BCTX stock?
BCTX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does BRIACELL THERAPEUTICS CORP belong to?
BRIACELL THERAPEUTICS CORP (BCTX) operates in the Health Care sector and the Biotechnology industry.
Should I buy BCTX stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BCTX.
BCTX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to BCTX. When comparing the yearly performance of all stocks, BCTX is a bad performer in the overall market: 93.82% of all stocks are doing better.
BCTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BCTX. The financial health of BCTX is average, but there are quite some concerns on its profitability.
BCTX Financial Highlights
Over the last trailing twelve months BCTX reported a non-GAAP Earnings per Share(EPS) of -128.19. The EPS decreased by -14343.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -119.59% | ||
| ROE | -146.16% | ||
| Debt/Equity | 0 |